Growing Demand for Next-Generation Antibody Therapeutics Drives Next-Generation Antibody Market Growth
According to our new research study on "Next-Generation Antibody Market Forecast to 2028 - COVID-19 Impact and Global Analysis - by Therapeutic Area, and Technology," the market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,468.41 million in 2021; it is estimated to grow at a CAGR of 11.9% during 2021-2028.
The report focuses on current market trends and growth drivers, including the growing global incidence of cancer and rising demand for advanced antibodies. However, growth is hindered by difficulties in production and obtaining regulatory approval.
Advanced antibody therapies are considered next-generation due to their improved effectiveness, safety, and ability to target specific ailments. Currently, many of these therapies are only available in clinical trials due to a lack of regulatory approval from agencies like the FDA. However, approval is expected in the next five years, driven by advancements in monoclonal antibody technology and increased investment from the biopharmaceutical and pharmaceutical industries. Additionally, contract development and manufacturing organizations (CDMOs) are connecting with next-generation antibody conjugates to provide comprehensive antibody-drug conjugate (ADC) services, further driving the growth of next-generation antibody market. CDMOs are enhancing their site-specific linker technologies, broadening their payload options, and exploring treatments beyond cancer. For example, in September 2020, MilliporeSigma invested US$ 65 million to expand its production of high potency active pharmaceutical ingredients (HPAPIs) and active pharmaceutical ingredients at its Madison, WI facility. In July 2019, REGENXBIO and Neurimmune AG joined forces to develop new AV gene treatments using NAV vectors to deliver human antibodies for treating neurodegenerative disorders like tauopathies. The growth of the next-generation antibody market is expected to be substantial during the forecast period due to increasing clinical trial approvals and the widespread use of next-generation antibodies for various diseases.
In 2021, North America had the largest share of the global next-generation antibody market. This growth is driven by factors such as the widespread adoption of technology advancements, growing R&D efforts in next-generation antibodies, growing use of these antibodies, and the presence of significant healthcare companies.
F. HOFFMANN-LA ROCHE LTD.; Kyowa Kirin Co., Ltd.; Seagen Inc.; ImmunoGen, Inc.; Takeda Pharmaceutical Company Limited; Amgen Inc.; Pfizer Inc.; Catalent Inc; AstraZeneca; and Xencor are major key players in the next-generation antibody market.
The next-generation antibody market is divided into two therapeutic areas: oncology and autoimmune/inflammatory. By technology, the next-generation antibody industry includes antibody-drug conjugates, bispecific antibodies, fc engineered antibodies, antibody fragments and antibody-like proteins, and biosimilar antibody products. The next-generation antibody market is further segmented by geography into five regions: North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East and Africa (the UAE, Saudi Arabia, South Africa, and the Rest of the Middle East and Africa), and South and Central America (Brazil, Argentina, and the rest of South and Central America).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com